一种新的热放疗治疗计划框架
本研究提出一种将热增敏与直接热细胞毒性逐体素纳入等效2Gy分次剂量(EQD2)优化的热放疗计划框架,并在4例前列腺癌病例中比较三种策略。结果显示,考虑热效应的均匀靶区EQD2策略可提高肿瘤控制概率且不增加直肠正常组织并发症概率。
要点
- 新框架将逐体素热效应整合入基于EQD2的放疗优化。
- 在4例前列腺癌病例中,RTHT+HT策略的肿瘤控制概率平均94.4%,直肠正常组织并发症概率平均8.4%。
- 实现上述获益依赖准确的肿瘤与组织特异性数据及热效应精确定量。
核心结论
- 本研究提出一种将热效应整合入基于EQD2放疗优化的创新热放疗计划方法。
- 结果表明,与传统方法相比,该框架能在不同温度分布下实现更高且均匀的靶区EQD2和肿瘤控制概率,同时不增加正常组织EQD2或正常组织并发症概率。
- 作者指出,尽管有望改善临床结局,但可实现的增益取决于准确的肿瘤与组织特异性数据以及热效应的精确定量。
研究设计与样本
- 本研究为计划框架的概念验证研究,针对4例温度分布差异显著的前列腺癌病例制定三种包含20次放疗分次的策略。
- 策略一为常规放疗计划60 Gy联合4次热疗(RT60+HT)。
- 策略二为无热疗的单独均匀剂量递增至68 Gy(RT68)。
- 策略三为在考虑4次热疗逐体素热效应且不增加正常组织剂量的条件下,最大化肿瘤控制概率的均匀靶区EQD2(RTHT+HT)。
- 评估包括剂量、EQD2、肿瘤控制概率和直肠正常组织并发症概率,并针对参数不确定性进行肿瘤控制概率和正常组织并发症概率的稳健性分析。
主要发现
- 无热疗时RT60的估计肿瘤控制概率约为76%,RT60+HT平均为85.9%(范围81.3%-90.5%),RT68为92.5%(92.4%-92.5%),RTHT+HT为94.4%(91.7%-96.6%)。
- 对应的平均直肠正常组织并发症概率分别为8.7%(7.9%-10.0%)、14.9%(13.8%-17.1%)和8.4%(7.5%-9.7%)。
- 与RT60+HT相比,RT68和RTHT+HT对参数不确定性的肿瘤控制概率稳健性略有增强。
- 与其他计划策略相比,RT68的直肠正常组织并发症概率更高且稳健性更差。
局限性
- 作者指出,可实现的增益取决于准确的肿瘤与组织特异性数据以及热效应的精确定量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Thermoradiotherapy combines radiation therapy with hyperthermia to increase therapeutic effectiveness. Currently, both modalities are optimized separately and in state-of-the-art research the enhanced therapeutic effect is evaluated using equivalent radiation dose in 2-Gy fractions (EQD2). This study proposes a novel thermoradiotherapy treatment planning framework with voxelwise EQD2 radiation therapy optimizing including thermal radiosensitization and direct thermal cytotoxicity. METHODS AND MATERIALS: To demonstrate proof-of-concept of the planning framework, 3 strategies consisting of 20 radiation therapy fractions were planned for 4 prostate cancer cases with substantially different temperature distributions: (1) Conventional radiation therapy plan of 60 Gy combined with 4 hyperthermia sessions (RT60 + HT), (2) standalone uniform dose escalation to 68 Gy without hyperthermia (RT68), and (3) uniform target EQD2 that maximizes the tumor control probability (TCP) accounting for voxelwise thermal effects of 4 hyperthermia sessions without increasing normal tissue doses (RTHT + HT). Assessment included dose, EQD2, TCP, and rectal normal tissue complication probability (NTCP), alongside robustness analyses for TCP and NTCP against parameter uncertainties. RESULTS: The estimated TCP of around 76% for RT60 without hyperthermia was increased to an average of 85.9% (range, 81.3%-90.5%) for RT60 + HT, 92.5% (92.4%-92.5%) for RT68, and 94.4% (91.7%-96.6%) for RTHT + HT. The corresponding averaged rectal NTCPs were 8.7% (7.9%-10.0%), 14.9% (13.8%-17.1%), and 8.4% (7.5%-9.7%), respectively. RT68 and RTHT + HT exhibited slightly enhanced TCP robustness against parameter uncertainties compared with RT60 + HT, and RT68 presented higher and less robust rectal NTCP values compared with the other planning strategies. CONCLUSIONS: This study introduces an innovative thermoradiotherapy planning approach, integrating thermal effects into EQD2-based radiation therapy optimization. Results demonstrate an ability to achieve enhanced and uniform target EQD2 and TCP across various temperature distributions without elevating normal tissue EQD2 or NTCP compared with conventional methods. Although promising for improving clinical outcomes, realizable enhancements depend on accurate tumor- and tissue-specific data and precise quantification of hyperthermic effects, which are seamlessly integrable in the planning framework as they emerge.
引用
- Ödén J, Eriksson K, Pavoni B, et al. A Novel Framework for Thermoradiotherapy Treatment Planning. Int J Radiat Oncol Biol Phys. 2024. PMID: 38387812. doi:10.1016/j.ijrobp.2024.02.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。